{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T14:34:20Z","timestamp":1791815660541,"version":"4.3.4"},"reference-count":41,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2014,2,14]],"date-time":"2014-02-14T00:00:00Z","timestamp":1392336000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Movement Disorders"],"published-print":{"date-parts":[[2014,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>It is believed that glycogen synthase kinase\u20103 (GSK\u20103) hyperphosphorylates tau protein in progressive supranuclear palsy (PSP). The Tau Restoration on PSP (TAUROS) study was a double\u2010blind, placebo\u2010controlled, randomized trial to assess the efficacy, safety, and tolerability of tideglusib, a GSK\u20103 inhibitor, as potential treatment for PSP. The study enrolled 146 PSP patients with mild\u2010to\u2010moderate disease who were randomized to receive once\u2010daily 600 mg tideglusib, 800 mg tideglusib, or placebo (ratio, 2:2:1) administered orally over 52 weeks. The primary endpoint was the change from baseline to week 52 on the PSP rating scale. Secondary endpoints were safety and tolerability of tideglusib, changes in motor function (the Timed Up and Go Test), cognition (Dementia Rating Scale\u20102, Frontal Assessment Battery, verbal fluency), apathy (Starkstein scale), activities of daily living (Schwab and England scale; Unified Parkinson's Disease Rating Scale, part II), quality of life (EuroQol), and Global Clinical Assessment. Brain atrophy on magnetic resonance imaging and several biomarkers in plasma and cerebrospinal fluid also were examined. No significant differences were detected in the primary or secondary endpoints at week 52 between placebo and either dose of tideglusib. Tideglusib was safe, with the exception of some asymptomatic, transient, and reversible transaminase elevations (mainly alanine aminotransferase) in 9% of patients, and diarrhea in 13% of patients. Tideglusib was generally well tolerated but it did not show clinical efficacy in patients with mild\u2010to\u2010moderate PSP. \u00a9 2014 International Parkinson and Movement Disorder Society<\/jats:p>","DOI":"10.1002\/mds.25824","type":"journal-article","created":{"date-parts":[[2014,2,17]],"date-time":"2014-02-17T05:45:49Z","timestamp":1392615949000},"page":"470-478","source":"Crossref","is-referenced-by-count":305,"title":["A phase 2 trial of the GSK\u20103 inhibitor tideglusib in progressive supranuclear palsy"],"prefix":"10.1002","volume":"29","author":[{"given":"Eduardo","family":"Tolosa","sequence":"first","affiliation":[{"name":"Neurology Service, Hospital Clinic de Barcelona Universidad de Barcelona Institut d'Investigacions Biom\u00e9diques August Pi i Sunyer (IDIBAPS), Centro de Investigaci\u00f3n Biom\u00e9dica en Red sobre Enfermedades Neurodegenerativas (CIBERNED) Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Litvan","sequence":"additional","affiliation":[{"name":"Movement Disorders Program University of California San Diego San Diego California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fcnter U.","family":"H\u00f6glinger","sequence":"additional","affiliation":[{"name":"Department of Neurology Philipps Universitat Marburg Germany"},{"name":"Department of Neurology Technische Universit\u00e4t, M\u00fcnchen, German Center for Neurodegenerative Diseases (DZNE) M\u00fcnchen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Burn","sequence":"additional","affiliation":[{"name":"Institute for Ageing and Health Newcastle University Newcastle Upon Tyne United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Lees","sequence":"additional","affiliation":[{"name":"Reta Lila Weston Institute London United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda V.","family":"Andr\u00e9s","sequence":"additional","affiliation":[{"name":"Clinical Department Noscira SA Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bel\u00e9n","family":"G\u00f3mez\u2010Carrillo","sequence":"additional","affiliation":[{"name":"Clinical Department Noscira SA Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Le\u00f3n","sequence":"additional","affiliation":[{"name":"Clinical Operations and Medical Affairs Department Noscira SA Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teodoro","family":"del Ser","sequence":"additional","affiliation":[{"name":"Medical Department Noscira SA Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the TAUROS Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,2,14]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(09)70042-0"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.2174\/1567205052772713"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tibs.2003.12.004"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2004.07.006"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(02)00161-8"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroscience.2010.05.044"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M109.067785"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1471-4159.2001.00495.x"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2004.11.012"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/nn.2785"},{"key":"e_1_2_9_12_1","first-page":"533","article-title":"Glycogen synthase kinase\u20103 (GSK\u20103) inhibitors reach the clinic","volume":"11","author":"Medina M","year":"2011","journal-title":"Curr Opin Drug Discov Devel"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awq115"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.2004.02422.x"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm011020u"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M111.306472"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2009.05.025"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2011.09.002"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.1004-07.2007"},{"key":"e_1_2_9_20_1","first-page":"205","article-title":"Treatment of Alzheimer's disease with the GSK\u20103 inhibitor tideglusib: a pilot study","volume":"33","author":"Ser T","year":"2013","journal-title":"J Alzheimers Dis"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.25815"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.47.1.1"},{"key":"e_1_2_9_23_1","first-page":"A326","article-title":"The Medical Advisory Board of the Society for Progressive Supranuclear Palsy. A clinical rating scale and staging system for progressive supranuclear palsy","volume":"48","author":"Golbe LI","year":"1997","journal-title":"Neurology"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.32.6.1318"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awm032"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.1991.tb01616.x"},{"key":"e_1_2_9_27_1","volume-title":"Dementia Rating Scale\u20102 Professional Manual","author":"Jurica PJ","year":"2001"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.55.11.1621"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1176\/jnp.4.2.134"},{"key":"e_1_2_9_30_1","first-page":"152","volume-title":"Third Symposium on Parkinson's Disease","author":"Schwab RS","year":"1969"},{"key":"e_1_2_9_31_1","series-title":"Recent Developments in Parkinson's Disease","first-page":"153","author":"Fahn S","year":"1987"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.3109\/07853890109002087"},{"key":"e_1_2_9_33_1","first-page":"218","volume-title":"ECDEU Assessment Manual for Psychopharmacology","author":"Guy W","year":"1976"},{"key":"e_1_2_9_34_1","volume-title":"Guidance for Industry on Drug\u2010Induced Liver Injury: Premarketing Clinical Evaluation: Drug Safety","author":"US Department of Health and Human Services","year":"2009"},{"key":"e_1_2_9_35_1","first-page":"533","article-title":"Glycogen synthase kinase\u20103 (GSK\u20103) inhibitors reach the clinic","volume":"11","author":"Medina M","year":"2008","journal-title":"Curr Opin Drug Discov Devel"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awn291"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2009.04.1231"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0404.2001.103002123.x"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.2522\/ptj.20070302"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.22023"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.57.3.467"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.41.7.986"}],"container-title":["Movement Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmds.25824","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mds.25824","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T09:26:01Z","timestamp":1760952361000},"score":1,"resource":{"primary":{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/10.1002\/mds.25824"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2,14]]},"references-count":41,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,4]]}},"alternative-id":["10.1002\/mds.25824"],"URL":"https:\/\/doi.org\/10.1002\/mds.25824","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.718278500.793497389","asserted-by":"object"}]},"ISSN":["0885-3185","1531-8257"],"issn-type":[{"value":"0885-3185","type":"print"},{"value":"1531-8257","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,2,14]]}}}